Everolimus and Octreotide Acetate With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors That Cannot Be Removed by Surgery

Conditions:   Gastrinoma;   Glucagonoma;   Insulinoma;   Pancreatic Alpha Cell Adenoma;   Pancreatic Alpha Cell Carcinoma;   Pancreatic Beta Islet Cell Adenoma;   Pancreatic Beta Islet Cell Carcinoma;   Pancreatic Delta Cell Adenoma;   Pancreatic Delta Cell Carcinoma;   Pancreatic G-cell Adenoma;   Pancreatic G-cell Carcinoma;   Pancreatic Polypeptide Tumor;   Recurrent Islet Cell Carcinoma;   Recurrent Pancreatic Cancer;   Somatostatinoma;   Stage III Pancreatic Cancer;   Stage IV Pancreatic CancerInterventions:   Drug: everolimus;   Drug: octreotide acetate;   Biological: bevacizumabSponsor:   National Cancer Institute (NCI)Active, not recruiting - verified July 2014
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials